Treatment for Type 2 Diabetes: Saxaglipt
Article Sidebar
Main Article Content
Abstract
No Abstract
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Ahren, B. Clinical results of treating type 2 diabeticpatients with sitagliptin, vildagliptin orsaxagliptin--diabetes control and potentialadverse events. Best Pract Res Clin EndocrinolMetab 2009; 23(4): 487-498.
Ammirati, MJ, Andrews, KM, et al. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-y l)-pyrrolidin-2-yl]-methanone: a potent, selective, orallyactive dipeptidyl peptidase IV inhibitor. BioorgMed Chem Lett 2009; 19(7): 1991-1995.
Anonymous. Saxagliptin (Onglyza) for type 2diabetes. Med Lett Drugs Ther 2009;51(1324): 85-886.
Barnett, AH. New treatments in type 2 diabetes: afocus on the incretin-based therapies. ClinEndocrinol (Oxf) 2009; 70(3): 343-353.
Chacra, AR, Tan, GH, et al. Saxagliptin added to asubmaximal dose of sulphonylurea improvesglycaemic control compared with uptitration ofsulphonylurea in patients with type 2 diabetes:a randomised controlled trial. Int J Clin Pract2009; 63(9): 1395-1406.
Combettes, MM. GLP-1 and type 2 diabetes:physiology and new clinical advances. CurrOpin Pharmacol 2006; 6(6): 598-605.
Deacon, CF and Holst, JJ. Saxagliptin: a new dipeptidylpeptidase-4 inhibitor for the treatment of type2 diabetes. Adv Ther 2009; 26(5):488-499.
DeFronzo, RA, Hissa, MN, et al. The efficacy andsafety of saxagliptin when added to metformintherapy in patients with inadequately controlledtype 2 diabetes with metformin alone.Diabetes Care 2009; 32(9): 1649-1655.
Focosi, D, Kast, RE, et al. Enhancement of hematopoietic stem cell engraftment by inhibition ofCXCL12 proteolysis with sitagliptin, an oraldipeptidyl-peptidase IV inhibitor: a report in acase of delayed graft failure. Leuk Res 2009;33(1): 178-181.
Goke, B, Gallwitz, B, et al. Saxagliptin is non-inferiorto glipizide in patients with type 2 diabetesmellitus inadequately controlled on metforminalone: a 52-week randomised controlled trial.International Journal of Clinical Practice 2010;64(12): 1619-1631.
Havale, SH and Pal, M. Medicinal chemistryapproaches to the inhibition of dipeptidylpeptidase-4 for the treatment of type 2diabetes. Bioorg Med Chem 2009; 17(5):1783-1802.
Hollander, P, Li, J, et al. Saxagliptin added to athiazolidinedione improves glycemic control inpatients with type 2 diabetes and inadequatecontrol on thiazolidinedione alone. J ClinEndocrinol Metab 2009; 94(12):4810-4819.
Kulasa, K and Edelman, S. Saxagliptin: the evidencefor its place in the treatment of type 2 diabetesmellitus. Core Evid 2010; 5: 23-37.
Mulakayala, N, Reddy Ch, U, et al. Synthesis ofdipeptidyl peptidase-4 inhibitors: a briefoverview. Tetrahedron 2010; 66(27-28):4919-4938.
Rosenstock, J, Aguilar-Salinas, C, et al. Effect ofsaxagliptin monotherapy in treatment-naivepatients with type 2 diabetes. Curr Med ResOpin 2009; 25(10): 2401-2411.
Sharma, M. Role of saxagliptin as monotherapy oradjunct therapy in the treatment of type 2diabetes. Ther Clin Risk Manag 2010; 6:233-237.
Singh, S, Sethi, S, et al. RBx-0597, a potent,selective and slow-binding inhibitor of dipeptidylpeptidase-IV for the treatment of type 2diabetes. Eur J Pharmacol 2010; [Epub aheadof print].
Tahrani, AA, Piya, MK, et al. Saxagliptin: a newDPP-4 inhibitor for the treatment of type 2diabetes mellitus. Adv Ther 2009; 26(3):249-262.
Tahrani, AA, Piya, MK, et al. Glycaemic control intype 2 diabetes: targets and new therapies.Pharmacol Ther 2010; 125(2): 328-361.
Thornberry, NA and Gallwitz, B. Mechanism of actionof inhibitors of dipeptidyl-peptidase-4(DPP-4). Best Pract Res Clin EndocrinolMetab 2009; 23(4): 479-486.
Yu, BS and Wang, AR. Glucagon-like peptide 1 basedtherapy for type 2 diabetes. World J Pediatr2008; 4(1): 8-13.